Camurus AB (publ) (CAMRF)
OTCMKTS
· Delayed Price · Currency is USD
56.00
0.00 (0.00%)
At close: May 19, 2025
Camurus AB Revenue
Camurus AB had revenue of 558.34M SEK in the quarter ending March 31, 2025, with 43.17% growth. This brings the company's revenue in the last twelve months to 2.04B, up 11.69% year-over-year. In the year 2024, Camurus AB had annual revenue of 1.87B with 8.78% growth.
Revenue (ttm)
2.04B SEK
Revenue Growth
+11.69%
P/S Ratio
15.14
Revenue / Employee
7.95M SEK
Employees
256
Market Cap
3.07B USD
Revenue Chart
* This company reports financials in SEK.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 1.87B | 150.73M | 8.78% |
Dec 31, 2023 | 1.72B | 760.51M | 79.52% |
Dec 31, 2022 | 956.34M | 355.77M | 59.24% |
Dec 31, 2021 | 600.57M | 264.57M | 78.74% |
Dec 31, 2020 | 336.00M | 230.39M | 218.16% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Endo Inc. | 1.73B |
Veradigm | 588.02M |
Tian'an Technology Group | 1.78M |
Elite Pharmaceuticals | 70.00M |
Glass House Brands | 215.62M |
Northwest Biotherapeutics | 1.47M |
Silence Therapeutics | 27.70M |
American Oncology Network | 1.76B |
Camurus AB News
- 4 weeks ago - CHMP recommends approval of Oczyesa® for treatment of acromegaly in the EU - PRNewsWire
- 7 months ago - US FDA declines to approve Camurus' rare hormone disorder drug - Reuters
- 1 year ago - New publication shows effectiveness data for weekly and monthly buprenorphine injections in treating opioid dependence in individuals using fentanyl - PRNewsWire